Sibylla is an early-stage drug discovery company based on the enabling possibility of simulating the folding pathway from the amino acid sequence produced by the cell's ribosomes to the native state with atomic detail. Sibylla's computational platform identifies long-lived folding intermediate structures amenable to host druggable pockets, constituting a new class of pharmacological targets. Sibylla's small molecules bind the folding intermediate state and interfere with the folding process causing degradation. Well-differentiated in the TPD landscape, Sibylla's Folding Interfering Degraders can be used against undruggable proteins, delivering new therapies for untreatable diseases. The internal pipeline is now progressing toward preclinical validation.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Italy
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Cyclin D1 degrader
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
